Promising kidney drug fails in large clinical trial

October 27, 2011

Washington, DC (Thursday, October 27, 2011) -- What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results call into question the usefulness of the drug sulodexide.

Kidney disease due to diabetes is the most common cause of kidney failure in developed countries. The number of patients with type 2 diabetes is expected to double and reach 366 million individuals worldwide by 2030. Kidney disease cases are sure to rise in parallel.

Investigators have wondered whether sulodexide, which belongs to a class of drugs called glycosaminoglycans, may protect the kidneys. The drug is actually a naturally occurring compound and has been used for more than 20 years to treat various heart conditions. Previous research indicates that sulodexide reduces excretion of protein in the urine, which is a hallmark of kidney disease.

To test the effects of sulodexide on the kidneys in a large and extensive trial, David Packham, MD (Melbourne Renal Research Group, in Australia) and his colleagues within the Collaborative Study Group (a large clinical trial group comprised of various kidney care centers) conducted a randomized, double-blind, placebo-controlled study in patients with diabetes and kidney disease. The investigators planned to enroll 2,240 patients in the Sun-MACRO trial over a period of two years, but they stopped the study early after enrolling 1,248 patients because they did not detect any significant differences between sulodexide and placebo for preventing kidney failure. Also, the trial did not confirm the potentially beneficial effect of sulodexide in reducing urinary protein excretion that was previously reported in smaller studies.

"In view of the negative results of Sun-MICRO trial and the data analysis from this study, it is tempting to conclude that sulodexide has no therapeutic benefit in type 2 diabetic nephropathy," the authors wrote.
Study co-authors include Rory Wolfe, PhD, Anne Reutens, MD, Sara Ivory, Robert Atkins, MD (Monash University, in Melbourne, Australia); Tomas Berl, MD (University of Colorado, in Denver); Hiddo Lambers Heerspink, PhD, Dick de Zeeuw, MD, PhD (University Medical Centre Groningen, in the Netherlands); Richard Rohde (the Collaborative Study Group); Julia Lewis, MD (Vanderbilt University Medical Center); Itamar Raz, MD (Hadaza Hebrew University, in Jerusalem, Israel); Thomas Wiegmann, MD (Veterans Affairs Medical Center, in Kansas City); Juliana Chan, MD (Prince of Wales Hospital, in Hong Kong, China); and Edmund Lewis, MD (Rush University Medical Center); for the Collaborative Study Group.

Disclosures: This study was funded entirely by Keryx Biopharmaceuticals.

The article, entitled "Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy," will appear online at on Thursday, October 27, 2011, doi:10.1681/ASN.2011040378.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

American Society of Nephrology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to